Colospa: Expert Relief for Irritable Bowel Syndrome Discomfort
| Product dosage: 135mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.99 | $59.27 (0%) | 🛒 Add to cart |
| 90 | $0.94 | $88.90 $84.38 (5%) | 🛒 Add to cart |
| 120 | $0.92 | $118.53 $110.50 (7%) | 🛒 Add to cart |
| 180 | $0.89 | $177.80 $160.72 (10%) | 🛒 Add to cart |
| 270 | $0.87 | $266.70 $236.06 (11%) | 🛒 Add to cart |
| 360 | $0.87
Best per pill | $355.60 $312.41 (12%) | 🛒 Add to cart |
Synonyms
| |||
Colospa (mebeverine hydrochloride) is a targeted antispasmodic agent specifically formulated for the symptomatic management of abdominal pain, cramping, and intestinal spasms associated with Irritable Bowel Syndrome (IBS). As a musculotropic antispasmodic with direct action on smooth muscle, it relieves gastrointestinal hypermotility without affecting normal gut motility. Its selective mechanism minimizes systemic side effects, making it a first-line choice for clinicians managing functional bowel disorders. Available in multiple formulations, it offers flexible dosing to suit individual patient needs and severity profiles.
Features
- Active ingredient: Mebeverine hydrochloride 135 mg
- Pharmaceutical form: Film-coated tablets
- Mechanism: Direct action on gastrointestinal smooth muscle
- Selective spasmolysis without anticholinergic effects
- Does not interfere with normal intestinal peristalsis
- Multiple dosage formulations available (tablets, capsules)
- Rapid onset of action (within 1-2 hours)
- Long duration of effect (up to 12 hours per dose)
- Minimal systemic absorption
- No development of tolerance with long-term use
Benefits
- Provides rapid relief from abdominal cramping and pain associated with IBS
- Reduces frequency and intensity of intestinal spasms without paralyzing gut motility
- Enables normalization of bowel function without causing constipation or diarrhea
- Allows patients to maintain daily activities and improve quality of life
- Minimizes systemic side effects compared to traditional anticholinergics
- Suitable for long-term management of chronic IBS symptoms
Common use
Colospa is primarily indicated for the symptomatic treatment of Irritable Bowel Syndrome (IBS), particularly when abdominal pain and spasm are predominant features. It is used in management of gastrointestinal motility disorders characterized by hypermotility, including spastic colon, mucous colitis, and gastrointestinal spasms of functional origin. The medication is particularly valuable for patients who experience postprandial discomfort, alternating bowel habits, and abdominal distension. Clinical use extends to adjunctive therapy in diverticular disease and other conditions where smooth muscle spasm contributes to symptomatology.
Dosage and direction
The recommended adult dosage is 135 mg (one tablet) three times daily, preferably taken 20 minutes before meals. Tablets should be swallowed whole with a glass of water and not chewed or crushed. For optimal effect, dosage should be spaced evenly throughout the day (approximately every 8 hours). Treatment duration depends on symptom control, with many patients requiring several weeks of continuous therapy. Dosage adjustment in elderly patients is generally not required, but renal or hepatic impairment may necessitate modified dosing under medical supervision. Pediatric use is not recommended due to insufficient safety data.
Precautions
Patients with known hypersensitivity to mebeverine hydrochloride or any excipients should avoid Colospa. Use with caution in patients with paralytic ileus or intestinal obstruction. While no specific precautions exist for cardiovascular patients, those with severe cardiac conditions should be monitored. Pregnancy category safety has not been fully established—use during pregnancy only if clearly needed and under medical supervision. Lactating women should consult their physician before use, as mebeverine may be excreted in breast milk. Patients should be advised that Colospa treats symptoms but does not cure underlying IBS pathology.
Contraindications
Colospa is contraindicated in patients with known hypersensitivity to mebeverine hydrochloride or any component of the formulation. Absolute contraindications include acute porphyria and mechanical bowel obstruction. The medication should not be used in children under 10 years of age due to lack of safety and efficacy data. Contraindication extends to patients with severe hepatic impairment where metabolism may be compromised. Those with pre-existing megacolon or toxic megacolon should avoid antispasmodic therapy. Concomitant use with other antispasmodics is generally contraindicated due to potential additive effects.
Possible side effect
Colospa is generally well-tolerated, with most adverse effects being mild and transient. Common side effects include dizziness (1-2% of patients), headache (1-3%), and mild gastrointestinal disturbances such as nausea or constipation. Rare cases of hypersensitivity reactions including skin rash, urticaria, and angioedema have been reported. Isolated cases of hepatic enzyme elevation may occur but typically resolve upon discontinuation. Cardiovascular effects are uncommon but may include palpitations in sensitive individuals. Most side effects diminish with continued therapy and rarely require discontinuation of treatment.
Drug interaction
Mebeverine hydrochloride has low protein binding and minimal metabolism through cytochrome P450 enzymes, resulting in few clinically significant drug interactions. However, theoretical interactions may occur with medications that affect gastrointestinal motility, such as opioids, anticholinergics, or prokinetic agents. Concurrent use with other spasmolytic agents may produce additive effects. No significant interactions have been documented with warfarin, oral contraceptives, or most cardiovascular medications. Patients taking multiple medications should still inform their healthcare provider to assess potential pharmacokinetic interactions.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed administration. Consistent dosing is important for maintaining therapeutic effect, but occasional missed doses are unlikely to significantly impact overall treatment efficacy. Patients should be educated to maintain regular dosing intervals for optimal symptom control.
Overdose
Cases of overdose are rare due to Colospa’s favorable safety profile. Symptoms of potential overdose may include increased severity of known side effects, particularly nervous system effects such as dizziness, headache, or excitation. Gastrointestinal symptoms might include nausea or abdominal discomfort. There is no specific antidote for mebeverine overdose. Treatment should be symptomatic and supportive, with particular attention to maintaining adequate hydration. Gastric lavage may be considered if ingestion occurred recently. Patients should seek immediate medical attention if overdose is suspected.
Storage
Store Colospa tablets at room temperature (15-30°C) in their original packaging to protect from light and moisture. Keep the container tightly closed and out of reach of children. Do not use tablets beyond the expiration date printed on the packaging. Avoid storage in bathrooms or other areas with high humidity. Proper storage ensures maintenance of pharmaceutical stability and efficacy throughout the product’s shelf life. Do not transfer tablets to other containers, as this may compromise product integrity.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Colospa is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Patients should not self-diagnose or self-medicate with this product. The prescribing physician should be consulted for proper diagnosis, dosage, and treatment duration. Individual response to medication may vary, and not all patients will experience the same results or side effects. This information does not replace comprehensive professional medical consultation.
Reviews
Clinical studies demonstrate Colospa’s efficacy in reducing IBS symptoms, with approximately 70-80% of patients experiencing significant improvement in abdominal pain and bloating. Gastroenterologists frequently report positive outcomes in patients with spasm-predominant IBS, noting particularly its favorable side effect profile compared to anticholinergic alternatives. Patient satisfaction surveys indicate improved quality of life measures, especially regarding reduced interruption of daily activities. Long-term follow-up studies show maintained efficacy without development of tolerance. Some reviews note the importance of combining pharmacological treatment with dietary and lifestyle modifications for optimal IBS management.